Thus, Trx1 inhibition sensitized MM cells to NF-кβ inhibitors suggesting that increased Trx1 levels may be responsible for the resistance of MM cells to NF-кβ-targeted therapies. The gene discussed is TXN; the disease is Miyoshi myopathy.